J&J Completes Firefly Bio Acquisition

Company Johnson & Johnson / Firefly Bio Event Type Acquisition Completion (Closing) Modality Degrader antibody conjugate (antibody-directed intracellular protein degradation) Asset Firelink platform (no nominated development candidate disclosed) Target Pan-KRAS and other difficult oncogenic drivers Disease Area Hard-to-treat solid tumors Summary Johnson & Johnson completed…